AOD-9604 5mg

Research Summary: What the Preclinical and Clinical Evidence Shows

The AOD 9604 research record spans foundational animal model studies, in vitro mechanistic data, and a clinical research program encompassing six clinical trials with more than 900 participants, making it one of the most studied compounds in the research peptide category.

AOD 9604 in Obese Animal Models: Foundational Preclinical Data

The foundational preclinical evidence on AOD 9604 comes from studies in obese mouse models examining the compound’s effects on lipid metabolism under chronic treatment conditions. Heffernan et al. (2001) compared AOD 9604 against full growth hormone in standard obese mice and beta-3 adrenergic receptor knockout mice, finding that AOD 9604 produced fat loss in both groups while the full growth hormone response differed between them.

This knockout model finding established that AOD 9604’s lipolytic activity operates through at least two distinct pathways, one receptor-dependent and one independent of beta-3 adrenergic receptor activation. The Heffernan et al. data remains among the most cited work in the AOD 9604 research literature.

Ng et al. (2000) examined AOD 9604 as a synthetic lipolytic domain of human growth hormone, characterizing its metabolic effects in preclinical models and providing foundational data on how structural reduction from full growth hormone to a 16-amino acid fragment changes the resulting compound’s metabolic profile.

Six Clinical Trials on AOD 9604: Scope and Scale

AOD 9604 has completed six clinical trials with more than 900 participants across the entire clinical research program, representing an unusually extensive human research dataset for a research peptide. The six clinical trials covered multiple dose levels, treatment durations, and participant populations, producing a broad safety data and tolerability data record.

The scale of the six clinical trials AOD 9604 completed positions it among the few research peptides with a formal Phase IIb randomized double blind placebo controlled study in its record, alongside earlier-phase clinical research designs.

The Phase IIb Trial: The Largest AOD 9604 Study

The largest trial within the AOD 9604 clinical research program was a Phase IIb study enrolling 536 participants with significant obesity. Participants received once-daily subcutaneous injections across a 12-week treatment period. The average body weight change observed was approximately 2.6 kg over the treatment period, and the trial did not reach statistically significant weight loss compared to the placebo group at the primary endpoint.

The Phase IIb data on AOD 9604 is cited both for the scale of participant enrollment and for the consistency of the directional body weight trend observed across the treatment period. The statistically significant weight loss threshold was not crossed in the primary analysis.

This Phase IIb outcome has been a reference point for researchers interpreting the broader AOD 9604 clinical research record, with the distinction between clinically meaningful fat loss trends and statistically significant weight loss as a regulatory endpoint being a recurring theme in published analysis.

Interpreting the AOD 9604 Weight Loss Evidence

The AOD 9604 clinical research record reflects a consistent directional trend in body weight and body composition data across six clinical trials and multiple dose levels, though statistically significant weight loss was not demonstrated in the Phase IIb primary endpoint.

Neither the preclinical data nor the clinical research on AOD 9604 supports claims of rapid dramatic weight loss or meaningful fat loss outcomes for human therapeutic use. AOD 9604 is not FDA-approved as an anti-obesity drug or for any other therapeutic application. Published research does not constitute medical advice or clinical practice guidance.

Safety Across the Clinical Research Program: No Serious Adverse Events

The safety profile of AOD 9604 across six clinical trials is defined by the absence of serious adverse events throughout the clinical research record. Stier et al. (2013) reported that the adverse event profile among AOD 9604-treated participants was comparable to the placebo group across the studies evaluated.

Adverse events deemed possibly related to AOD 9604 were mild and consisted of headaches and injection site reactions. Carpal tunnel syndrome and fluid retention, effects associated with full growth hormone, were not observed in AOD 9604 clinical research at the therapeutic doses studied. No participants developed antibodies against AOD 9604 across the clinical research program.

The no serious adverse events finding across more than 900 clinical research participants is an important benchmark for researchers designing safety-focused protocol comparisons involving metabolic research compounds.

AOD 9604 and IGF-1: Clinical Research Findings

One of the most important clinical research findings associated with AOD 9604 is its consistent lack of effect on IGF-1 levels across all participant populations studied. Full growth hormone triggers IGF-1 production as part of its mechanism, which subsequently affects insulin levels, blood glucose, and tissue growth signaling. AOD 9604 did not elevate IGF-1 in any of the clinical research populations examined.

This IGF-1 neutrality confirms that AOD 9604’s activity is restricted to the lipolytic domain identified in preclinical models, without triggering the broader hormonal cascade associated with growth hormone. For researchers examining targeted fat metabolism interventions, this is an important data point in compound selection and study design.

AOD 9604 in Combination Peptide Therapy Research Protocols

AOD 9604 has been referenced in combination peptide therapy research contexts alongside several other compounds under active investigation. Researchers have noted AOD 9604 in research protocols with CJC-1295 and Ipamorelin, which stimulate endogenous growth hormone production through mechanisms distinct from AOD 9604’s direct lipolytic pathway.

AOD 9604 has also been examined in research contexts alongside Tesamorelin, a GHRH analogue with documented fat metabolism effects, and with Semaglutide, a GLP-1 receptor agonist studied for its metabolic effects. AOD 9604 combined with NAD+ has been noted in protocols focused on metabolic support and mitochondrial function.

AOD 9604 is not FDA-approved for use in any combination therapy. No combination involving AOD 9604 has received regulatory approval for human therapeutic use. All combination research involving AOD 9604 remains within the preclinical and investigational research domain. Researchers designing combination peptide therapy protocols are responsible for complying with all applicable regulatory and institutional requirements.

AOD 9604 Research Protocol Specifications

Researchers incorporating AOD 9604 into study designs reference a consistent set of specifications from the published clinical research program. Subcutaneous injection is the established administration route in all published AOD 9604 research, with daily doses in the clinical trials ranging from 250 mcg to 500 mcg. Doses above 1 mg showed no additional benefit in the study populations examined.

Reconstitution of lyophilized AOD 9604 for subcutaneous injection research typically involves approximately 2 mL of bacteriostatic water per 5 mg vial. Researchers should reference the published clinical research record and applicable institutional protocols when designing AOD 9604 study parameters.

Research Summary

Why Researchers Choose AOD 9604 from Azoth

Scientific research depends on compound consistency, documented purity, and reliable sourcing. Azoth provides AOD 9604 manufactured to strict purity specifications and backed by third-party Certificate of Analysis documentation for each production batch.

• 99%+ purity verified via HPLC testing
• USA-manufactured under strict quality protocols
• Third-party tested for identity, purity, and stability
• Lyophilized powder format for maximum shelf stability
• Certificate of Analysis available for every batch

Whether your research focus is fat metabolism mechanisms, adipose tissue biology, metabolic syndrome models, or body composition research in preclinical settings, Azoth provides the compound quality and documentation your laboratory research requires.

Researchers choosing AOD 9604 from Azoth can expect consistent lot-to-lot purity, transparent documentation, and a sourcing partner committed to quality standards that support reproducible preclinical outcomes.

AOD 9604 Storage and Handling

AOD 9604 is supplied in lyophilized (freeze-dried) powder form. Store at 2-8 degrees Celsius in a cool, dry environment away from direct light and moisture. After reconstitution with bacteriostatic water, keep refrigerated and use in accordance with your laboratory research protocol. Stability of lyophilized AOD 9604 is maintained for up to 24 months under appropriate storage conditions.

Legal Disclaimer

AOD 9604 sold by Azoth is intended for laboratory and in vitro research use only. It is not approved by the Food and Drug Administration (FDA) for human consumption, medical use, diagnostic procedures, or veterinary use. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. This content does not constitute medical advice. Bodily introduction of any kind into humans or animals is strictly prohibited by law. All purchasers must be licensed researchers or qualified laboratory professionals. By purchasing this product, you acknowledge that you are aware of the applicable regulations in your jurisdiction and that you will use this compound exclusively within a qualified research environment.